Long-term survivors of anti-ICOS mAb have sublethal GVHD
. | Experiment 1 . | . | Experiment 2 . | . | ||
|---|---|---|---|---|---|---|
| Organ . | BM only . | Anti-ICOS . | Rad control . | Anti-ICOS . | ||
| Colon | ||||||
| Mouse 1 | 1 | 2 | 1 | 1.5 | ||
| Mouse 2 | 1 | 1.5 | 1.5 | 1 | ||
| Mouse 3 | 1 | 2 | 1 | 2 | ||
| Mouse 4 | 1 | 2 | 1.5 | 3 | ||
| Average GVHD score ± SD | 1.0 ± 0.00 | 1.9 ± 0.25* | 1.3 ± 0.29 | 1.9 ± 0.85 | ||
| Liver | ||||||
| Mouse 1 | 3 | 3 | 0.5 | 3 | ||
| Mouse 2 | 2 | 3.5 | 0.5 | 0.5 | ||
| Mouse 3 | 1 | 3 | 0 | 2 | ||
| Mouse 4 | 1.5 | 3.5 | 0.5 | 2 | ||
| Average GVHD score ± SD | 1.9 ± 0.85 | 3.3 ± 0.29* | 0.4 ± 0.25 | 1.9 ± 1.03* | ||
| Lung | ||||||
| Mouse 1 | 3 | 2 | 1 | 2 | ||
| Mouse 2 | 2 | 3.5 | 1 | 1 | ||
| Mouse 3 | 2.5 | 3 | 0.5 | 3 | ||
| Mouse 4 | 2 | 3.5 | 0.5 | 2.5 | ||
| Average GVHD score ± SD | 2.4 ± 0.48 | 3.0 ± 0.71 | 0.8 ± 0.29 | 2.1 ± 0.85* | ||
| Skin | ||||||
| Mouse 1 | 0.5 | 0.5 | 0.5 | 0 | ||
| Mouse 2 | 1 | 0.5 | 0.5 | 0 | ||
| Mouse 3 | 1 | 1.5 | 0.5 | 0.5 | ||
| Mouse 4 | 0.5 | 1 | 0.5 | 0.5 | ||
| Average GVHD score ± SD | 0.8 ± 0.29 | 0.9 ± 0.48 | 0.5 ± 0.00 | 0.3 ± 0.29 | ||
| Spleen | ||||||
| Mouse 1 | 1.5 | 2.5 | 0.5 | 2 | ||
| Mouse 2 | 2 | 3 | 0.5 | 1 | ||
| Mouse 3 | 1 | 3 | 0.5 | 1 | ||
| Mouse 4 | 0.5 | 3.5 | 0.5 | 1 | ||
| Average GVHD score ± SD | 1.3 ± 0.65 | 3.0 ± 0.41* | 0.5 ± 0.00 | 1.3 ± 0.50* | ||
. | Experiment 1 . | . | Experiment 2 . | . | ||
|---|---|---|---|---|---|---|
| Organ . | BM only . | Anti-ICOS . | Rad control . | Anti-ICOS . | ||
| Colon | ||||||
| Mouse 1 | 1 | 2 | 1 | 1.5 | ||
| Mouse 2 | 1 | 1.5 | 1.5 | 1 | ||
| Mouse 3 | 1 | 2 | 1 | 2 | ||
| Mouse 4 | 1 | 2 | 1.5 | 3 | ||
| Average GVHD score ± SD | 1.0 ± 0.00 | 1.9 ± 0.25* | 1.3 ± 0.29 | 1.9 ± 0.85 | ||
| Liver | ||||||
| Mouse 1 | 3 | 3 | 0.5 | 3 | ||
| Mouse 2 | 2 | 3.5 | 0.5 | 0.5 | ||
| Mouse 3 | 1 | 3 | 0 | 2 | ||
| Mouse 4 | 1.5 | 3.5 | 0.5 | 2 | ||
| Average GVHD score ± SD | 1.9 ± 0.85 | 3.3 ± 0.29* | 0.4 ± 0.25 | 1.9 ± 1.03* | ||
| Lung | ||||||
| Mouse 1 | 3 | 2 | 1 | 2 | ||
| Mouse 2 | 2 | 3.5 | 1 | 1 | ||
| Mouse 3 | 2.5 | 3 | 0.5 | 3 | ||
| Mouse 4 | 2 | 3.5 | 0.5 | 2.5 | ||
| Average GVHD score ± SD | 2.4 ± 0.48 | 3.0 ± 0.71 | 0.8 ± 0.29 | 2.1 ± 0.85* | ||
| Skin | ||||||
| Mouse 1 | 0.5 | 0.5 | 0.5 | 0 | ||
| Mouse 2 | 1 | 0.5 | 0.5 | 0 | ||
| Mouse 3 | 1 | 1.5 | 0.5 | 0.5 | ||
| Mouse 4 | 0.5 | 1 | 0.5 | 0.5 | ||
| Average GVHD score ± SD | 0.8 ± 0.29 | 0.9 ± 0.48 | 0.5 ± 0.00 | 0.3 ± 0.29 | ||
| Spleen | ||||||
| Mouse 1 | 1.5 | 2.5 | 0.5 | 2 | ||
| Mouse 2 | 2 | 3 | 0.5 | 1 | ||
| Mouse 3 | 1 | 3 | 0.5 | 1 | ||
| Mouse 4 | 0.5 | 3.5 | 0.5 | 1 | ||
| Average GVHD score ± SD | 1.3 ± 0.65 | 3.0 ± 0.41* | 0.5 ± 0.00 | 1.3 ± 0.50* | ||
GVHD target tissues were harvested 4 months (experiment 1) and 7 months (experiment 2) from 4 surviving mice per group from the experiments graphed in Figure 1D (experiment 1) and Figure 3A (experiment 2). Tissues were sectioned and stained with hematoxylin and eosin and scored for GVHD histopathology. Shown are individual and average scores out of a maximum score of 4.0.
Rad represents radiation.
P ≤ .03.